{"id":777544,"date":"2025-12-03T13:45:01","date_gmt":"2025-12-03T13:45:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=777544"},"modified":"2025-12-03T13:45:01","modified_gmt":"2025-12-03T13:45:01","slug":"shilai-peptide-to-invest-32-million-in-stateoftheart-peptide-laboratory-in-hangzhou","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/shilai-peptide-to-invest-32-million-in-stateoftheart-peptide-laboratory-in-hangzhou_777544.html","title":{"rendered":"ShiLai Peptide to Invest $32 Million in State-of-the-Art Peptide Laboratory in Hangzhou"},"content":{"rendered":"
ShiLai Peptide\u2019s CEO, Luo Binhua, said the investment reflects the company\u2019s commitment to a \u201cnew science model\u201d that integrates research-driven development, controlled production, and specialized customer support.<\/div>\n

ShiLai Peptide<\/a>, a leading provider of high-purity, customizable research peptides, announced plans to invest $32 million to build a state-of-the-art peptide research and production laboratory<\/strong> in Hangzhou. The facility is designed to meet world-class GMP standards<\/strong>, aiming to strengthen ShiLai’s global supply of high-quality peptides for in vitro scientific research. The new laboratory will feature advanced lyophilization equipment, automated quality control systems, and cutting-edge production technology to support high-level molecular and cellular studies worldwide.<\/p>\n

ShiLai Peptide<\/strong>’s CEO, Luo Binhua, said the investment reflects the company’s commitment to a “new science model”<\/strong> that integrates research-driven development, controlled production, and specialized customer support. “This expansion will enable us to provide reliable, high-purity peptides to laboratories globally, allowing scientists to focus on molecular mechanisms and cell signaling studies without worrying about product stability or purity,” Luo said.<\/p>\n

Currently, ShiLai offers a range of research-grade peptide products, including Retatrutide Pen, lyophilized Retatrutide, Glow, and NAD<\/strong>. The Retatrutide Pen is a lyophilized peptide that must be reconstituted with sterile water and is intended strictly for in vitro laboratory research<\/strong>. It is not for human use or clinical applications<\/strong>. Retatrutide samples are ≥99.3% pure, available in 5mg, 10mg, 20mg, and 30mg specifications. Glow and NAD series also provide high-purity peptides for in vitro studies such as molecular mechanism research, signal pathway analysis, and cellular response experiments.<\/p>\n

ShiLai Peptide<\/strong>’s products are in strong demand across global research markets, currently selling well in the United Kingdom, Brazil, the United States, Morocco, France, Switzerland, and Canada<\/strong>, providing laboratories with reliable peptide solutions. To further advance international scientific collaboration, ShiLai is actively seeking partnerships with overseas laboratories.<\/p>\n

Through its “new science model,” ShiLai Peptide<\/strong> in Hangzhou delivers high-purity, customizable, and stable peptides for laboratory research while expanding its international collaboration network, helping laboratories worldwide achieve more precise in vitro research outcomes.<\/p>\n

For more information:<\/strong> https:\/\/retatrutidesupplier.com\/<\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> ShiLai Peptide Technologies<\/a>
Contact Person:<\/strong> Kenan
Email:<\/strong> Send Email<\/a>
City:<\/strong> Hangzhou
Country:<\/strong> China
Website:<\/strong> https:\/\/retatrutidesupplier.com\/<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

ShiLai Peptide\u2019s CEO, Luo Binhua, said the investment reflects the company\u2019s commitment to a \u201cnew science model\u201d that integrates research-driven development, controlled production, and specialized customer support. ShiLai Peptide, a leading provider of high-purity, customizable research peptides, announced plans to … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,412,406,420,411],"tags":[],"class_list":["post-777544","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-News-Current-Affairs","category-Pharmaceuticals-Biotech","category-Science","category-Technology"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/777544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=777544"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/777544\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=777544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=777544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=777544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}